医学
新颖性
队列
气流
队列研究
重症监护医学
内科学
机械工程
哲学
神学
工程类
作者
Richard Beasley,Rod Hughes,Àlvar Agustí,Peter Calverley,Bradley E. Chipps,Ricardo del Olmo,Alberto Papi,David Price,Hiroshi Inoue,Christer Janson,Maarten van den Berge,Helen K. Reddel,Hana Müllerová,Anastasios Mangelis,Eleni Rapsomaniki
出处
期刊:Annals of the American Thoracic Society
[American Thoracic Society]
日期:2025-09-17
标识
DOI:10.1513/annalsats.202412-1273oc
摘要
The clinical characteristics of persistent airflow limitation (PAL) were explored in patients aged ≥12 years with physician-assigned diagnoses of asthma, asthma plus chronic obstructive pulmonary disease (COPD), or COPD in the NOVEL Observational longiTudinal studY (NOVELTY) cohort. The NOVELTY study is a prospective study conducted in primary and secondary care in 18 countries. To determine the proportion of patients with PAL at baseline, their baseline characteristics, and the stability and prognostic utility of PAL during follow-up. PAL was defined as post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio less than the lower limit of the normal range (European Respiratory Society [ERS]/American Thoracic Society [ATS]) or as <0.7 (Global Initiative for Chronic Obstructive Lung Disease [GOLD] criteria). We studied 9,081 patients over 3 years (asthma: 4,754; asthma+COPD; 1,147; COPD: 3,180). Baseline prevalence of PAL was 24.2% and 29.2% (asthma), 63.3% and 74.1% (asthma+COPD), and 65.4% and 75.8% (COPD) using ERS/ATS and GOLD criteria, respectively. Patients with PAL had markedly worse symptom burden and a history of more frequent moderate and severe exacerbations. In patients with asthma PAL was associated with higher blood eosinophils and fractional exhaled nitric oxide (FeNO) values; 60% had never smoked. Of patients with PAL at baseline 84% continued to meet PAL criteria at Year 3. Irrespective of physician diagnosis, PAL was a marker of increased risk of moderate and severe exacerbations and poor symptom control during the 3-year follow-up. PAL is a stable trait, associated with more severe disease and poor outcomes in adults with a physician-assigned diagnosis of asthma and/or COPD. Clinical Trial Registration (if any): NOVELTY: NCT02760329.
科研通智能强力驱动
Strongly Powered by AbleSci AI